RxDoctor Payments DataLook up a doctor →

David Bryan, MD

Urology · Chesterfield, MONPI 1578671418

Payments from drug & device makers

$45,030in general payments, 2019–2025

Across 382 payments — averaging $117.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Accord Healthcare, Inc.$24K
  • Bayer$9K
  • Ferring Pharmaceuticals Inc.$3K
  • Medtronic$2K
  • Boston Scientific$1K
  • Dendreon Pharmaceuticals LLC$434
  • plus $7K from 47 others

What the payments were for

  • Consulting fees$19,57543%
  • Speaking & faculty fees$13,81031%
  • Travel & lodging$1,3773%
  • Food & beverage$10,19323%
  • Education$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,030 in reported general payments places this provider in the 90th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$582,114
Medicare patients
703
Services billed
7,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide112$1,538,042
NubeqaDarolutamide89$1,153,564
ErleadaApalutamide49$730,833
OrgovyxRelugolix118$305,993
MyrbetriqMirabegron83$60,135
GemtesaVibegron50$30,578
Tamsulosin Hcl1,007$12,992
Oxybutynin Chloride ErOxybutynin Chloride276$5,319
Fesoterodine Fumarate ErFesoterodine Fumarate23$4,042
Dutasteride184$3,841
Potassium Citrate ErPotassium Citrate37$3,149
Silodosin26$2,420
Finasteride219$2,405
Trospium Chloride36$2,100
NitrofurantoinNitrofurantoin Macrocrystal68$1,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$419$1,598,177195 claims
BayerNubeqa$8,732$1,153,56489 claims
Johnson & JohnsonErleada$432$730,83349 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$402$336,571168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 urology providers in Missouri.

Other urology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →